Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Retrospective real-world registry analysis confirming sustained drug survival of guselkumab across weight, BMI, and comorbidity strata over 36 months, with consistent outcomes but limited by observational design and missing baseline data.
Phase II single-blind RCT showing statistically significant improvement in combined symptom-medication score at 80 μg dose with robust immunological response, but limited by single-blind design, modest effect size, and need for Phase III confirmation.
A narrative review synthesizing epidemiology, pathophysiology, diagnosis, prevention and management of occupational contact dermatitis, with explicit separation of established evidence from hypothesis, positioned within WHO public health priorities.
A mechanistic review proposing pathways linking metabolic dysfunction to skin inflammation, supported by correlational evidence and emerging data, but lacking primary clinical trial evidence or definitive causal proof.
Journal of the European Academy of Dermatology and Venereology
Expert consensus recommendations synthesizing RCT and real-world evidence on malignancy risk with biologic and oral targeted therapies in psoriasis and atopic dermatitis, addressing a clinically important gap in populations excluded from trials.
A narrative literature review synthesizing mechanistic pathways between psoriasis and psychiatric comorbidity; raises integrated treatment questions but does not present original empirical data or controlled evidence comparing outcomes.